• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多基因风险评分与携带 BRCA1 和 BRCA2 致病性变异的个体的乳腺癌和上皮性卵巢癌风险。

Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.

机构信息

Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK.

The Netherlands Cancer Institute, Department of Epidemiology (PSOE), Amsterdam, The Netherlands.

出版信息

Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.

DOI:10.1038/s41436-020-0862-x
PMID:32665703
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7521995/
Abstract

PURPOSE

We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for BRCA1 and BRCA2 pathogenic variant carriers.

METHODS

Retrospective cohort data on 18,935 BRCA1 and 12,339 BRCA2 female pathogenic variant carriers of European ancestry were available. Three versions of a 313 single-nucleotide polymorphism (SNP) BC PRS were evaluated based on whether they predict overall, estrogen receptor (ER)-negative, or ER-positive BC, and two PRS for overall or high-grade serous EOC. Associations were validated in a prospective cohort.

RESULTS

The ER-negative PRS showed the strongest association with BC risk for BRCA1 carriers (hazard ratio [HR] per standard deviation = 1.29 [95% CI 1.25-1.33], P = 3×10). For BRCA2, the strongest association was with overall BC PRS (HR = 1.31 [95% CI 1.27-1.36], P = 7×10). HR estimates decreased significantly with age and there was evidence for differences in associations by predicted variant effects on protein expression. The HR estimates were smaller than general population estimates. The high-grade serous PRS yielded the strongest associations with EOC risk for BRCA1 (HR = 1.32 [95% CI 1.25-1.40], P = 3×10) and BRCA2 (HR = 1.44 [95% CI 1.30-1.60], P = 4×10) carriers. The associations in the prospective cohort were similar.

CONCLUSION

Population-based PRS are strongly associated with BC and EOC risks for BRCA1/2 carriers and predict substantial absolute risk differences for women at PRS distribution extremes.

摘要

目的

我们评估了基于人群的多基因风险评分(PRS)与 BRCA1 和 BRCA2 致病性变异携带者乳腺癌(BC)或上皮性卵巢癌(EOC)风险之间的关联。

方法

我们获得了 18935 名欧洲裔 BRCA1 和 12339 名 BRCA2 女性致病性变异携带者的回顾性队列数据。评估了三种基于是否预测总体、雌激素受体(ER)阴性或 ER 阳性 BC 的 313 个单核苷酸多态性(SNP)BC PRS 版本,以及两种用于总体或高级别浆液性 EOC 的 PRS。在一个前瞻性队列中验证了关联。

结果

ER 阴性 PRS 与 BRCA1 携带者的 BC 风险相关性最强(每标准差风险比 [HR] = 1.29 [95% CI 1.25-1.33],P = 3×10)。对于 BRCA2,最强的关联是总体 BC PRS(HR = 1.31 [95% CI 1.27-1.36],P = 7×10)。HR 估计值随年龄显著下降,并且存在预测变异对蛋白质表达影响的关联差异的证据。HR 估计值小于一般人群的估计值。高级别浆液性 PRS 与 BRCA1(HR = 1.32 [95% CI 1.25-1.40],P = 3×10)和 BRCA2(HR = 1.44 [95% CI 1.30-1.60],P = 4×10)携带者的 EOC 风险相关性最强。前瞻性队列中的关联相似。

结论

基于人群的 PRS 与 BRCA1/2 携带者的 BC 和 EOC 风险密切相关,并预测 PRS 分布极端的女性存在实质性的绝对风险差异。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3791/7521995/c949a191f18b/41436_2020_862_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3791/7521995/ee55cb099d65/41436_2020_862_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3791/7521995/c949a191f18b/41436_2020_862_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3791/7521995/ee55cb099d65/41436_2020_862_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3791/7521995/c949a191f18b/41436_2020_862_Fig2_HTML.jpg

相似文献

1
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants.多基因风险评分与携带 BRCA1 和 BRCA2 致病性变异的个体的乳腺癌和上皮性卵巢癌风险。
Genet Med. 2020 Oct;22(10):1653-1666. doi: 10.1038/s41436-020-0862-x. Epub 2020 Jul 15.
2
Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers.评估BRCA1和BRCA2突变携带者中用于乳腺癌和卵巢癌风险预测的多基因风险评分
J Natl Cancer Inst. 2017 Jul 1;109(7). doi: 10.1093/jnci/djw302.
3
Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores.使用多基因风险评分评估携带BRCA1和BRCA2致病变异的男性患乳腺癌和前列腺癌的风险。
J Natl Cancer Inst. 2022 Jan 11;114(1):109-122. doi: 10.1093/jnci/djab147.
4
Polygenic risk scores indicate extreme ages at onset of breast cancer in female BRCA1/2 pathogenic variant carriers.多基因风险评分提示携带 BRCA1/2 致病性变异的女性乳腺癌发病年龄极早。
BMC Cancer. 2022 Jun 27;22(1):706. doi: 10.1186/s12885-022-09780-1.
5
Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.BRCA1 和 BRCA2 突变携带者的癌症风险:EMBRACE 前瞻性分析的结果。
J Natl Cancer Inst. 2013 Jun 5;105(11):812-22. doi: 10.1093/jnci/djt095. Epub 2013 Apr 29.
6
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.19p13.1 和 ZNF365 位点的常见变异与 BRCA1 和 BRCA2 突变携带者的乳腺癌和卵巢癌的 ER 亚型风险相关。
Cancer Epidemiol Biomarkers Prev. 2012 Apr;21(4):645-57. doi: 10.1158/1055-9965.EPI-11-0888. Epub 2012 Feb 20.
7
Second Primary Cancer Risks After Breast Cancer in and Pathogenic Variant Carriers.BRCA1和BRCA2致病变异携带者患乳腺癌后的第二原发性癌症风险。
J Clin Oncol. 2025 Feb 20;43(6):651-661. doi: 10.1200/JCO.24.01146. Epub 2024 Oct 29.
8
The KL-VS sequence variant of Klotho and cancer risk in BRCA1 and BRCA2 mutation carriers.KL-VS 序列变异型 Klotho 与 BRCA1 和 BRCA2 突变携带者的癌症风险。
Breast Cancer Res Treat. 2012 Apr;132(3):1119-26. doi: 10.1007/s10549-011-1938-8. Epub 2012 Jan 3.
9
Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.BRCA1 或 BRCA2 预测性检测阴性者的乳腺癌或卵巢癌风险:来自 EMBRACE 研究的结果。
Genet Med. 2018 Dec;20(12):1575-1582. doi: 10.1038/gim.2018.44. Epub 2018 Mar 22.
10
The association between cancer family history and ovarian cancer risk in BRCA1/2 mutation carriers: can it be explained by the mutation position?BRCA1/2 基因突变携带者的癌症家族史与卵巢癌风险的关联:能否用突变位置来解释?
Eur J Hum Genet. 2018 Jun;26(6):848-857. doi: 10.1038/s41431-018-0111-9. Epub 2018 Feb 26.

引用本文的文献

1
Redefining Risk, Biomarkers, and Precision Therapy for Hereditary Ovarian Cancer: A Review.重新定义遗传性卵巢癌的风险、生物标志物和精准治疗:综述
ACS Omega. 2025 Aug 16;10(33):36890-36903. doi: 10.1021/acsomega.5c05260. eCollection 2025 Aug 26.
2
Standardization, Education, and Resourcing: The Way Forward for Implementing Polygenic Risk Scores in Hereditary Breast and Ovarian Cancer.标准化、教育与资源配置:遗传性乳腺癌和卵巢癌中实施多基因风险评分的未来之路
Clin Transl Sci. 2025 Aug;18(8):e70323. doi: 10.1111/cts.70323.
3
Considering Clinical Implementation of Polygenic Scores in Hereditary Cancer Risk Assessment: Recipients' Perspectives on Influencing Factors and Strategies.

本文引用的文献

1
Variation in BRCA1 cancer risks by mutation position.BRCA1癌症风险因突变位置而异。
Cancer Epidemiol Biomarkers Prev. 2002 Apr;11(4):329-36.
遗传性癌症风险评估中多基因评分的临床应用考量:接受者对影响因素及策略的看法
Patient. 2025 Jun 28. doi: 10.1007/s40271-025-00747-5.
4
Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer-Specific Polygenic Scores.使用癌症特异性多基因评分估计BRCA2致病变异携带者的癌症外显率。
Cancer Med. 2025 Jun;14(11):e70990. doi: 10.1002/cam4.70990.
5
Analysis of Lifestyle and Genetic Risk Factors in Urban Women in China Who Had Malignant or Suspected Malignant Breast Nodules Identified via Breast Cancer Screening.对在中国通过乳腺癌筛查发现患有恶性或疑似恶性乳腺结节的城市女性的生活方式和遗传风险因素的分析。
Breast Care (Basel). 2025 Mar 21:1-13. doi: 10.1159/000545279.
6
Insights into genetic modifiers of breast cancer risk in carriers of BRCA1 and BRCA2 pathogenic variants.对携带BRCA1和BRCA2致病变异的乳腺癌风险基因修饰因子的见解。
Hered Cancer Clin Pract. 2025 Apr 28;23(1):15. doi: 10.1186/s13053-025-00313-y.
7
The Spanish Polygenic Score reference distribution: a resource for personalized medicine.西班牙多基因评分参考分布:个性化医疗的一种资源。
Eur J Hum Genet. 2025 Apr 24. doi: 10.1038/s41431-025-01850-9.
8
Economic evaluation of personalised versus conventional risk assessment for women who have undergone testing for hereditary breast and ovarian cancer genes: a modelling study.针对已接受遗传性乳腺癌和卵巢癌基因检测的女性,个性化风险评估与传统风险评估的经济学评价:一项建模研究
J Med Genet. 2025 Jun 24;62(7):450-456. doi: 10.1136/jmg-2024-109948.
9
Multi-Trait Polygenic Risk Score, Nongenetic Determinants, and Cardiovascular Disease Death: A Cohort Study of 14 086 Japanese Individuals.多性状多基因风险评分、非遗传决定因素与心血管疾病死亡:一项对14086名日本个体的队列研究。
J Am Heart Assoc. 2025 Mar 18;14(6):e038572. doi: 10.1161/JAHA.124.038572. Epub 2025 Mar 13.
10
Genome sequencing enhances the diagnostic yield and expands the genetic landscape of male breast cancer.基因组测序提高了男性乳腺癌的诊断率,并拓展了其遗传图谱。
Genet Med Open. 2024 Nov 6;3:101899. doi: 10.1016/j.gimo.2024.101899. eCollection 2025.